Results from the world’s largest study investigating the ‘naturalistic’ use of psilocybin outside of research settings have shown lasting therapeutic benefits.
The European Medicines Agency (EMA) has updated its general guidelines on the development of medicinal products for Major Depressive Disorder (MDD) to include a section on...
California could decriminalise naturally occurring psychedelics and create a framework for their therapeutic use under a new bill.
MAPS PBC has published anticipated results from its Phase 3b study that could bring MDMA-assisted therapy closer to Food and Drug Administration (FDA) approval by 2024...
A new research review has explored the use of psilocybin for the treatment of resistant depression.
In a new policy briefing for the European Medicines Agency (EMA), Psychedelic Access and Research European Alliance (PAREA) has called for an advisory body on psychedelics...
Findings from a landmark survey have revealed that people with experience using psychedelics exhibited elevated psychological well-being during the COVID-19 pandemic.
A new survey study carried out by The Beckley Foundation and Maastricht University has found that classical psychedelics such as psilocybin and LSD could have painkilling...
In the latest development for psychedelics in the UK, the Home Affairs Committee Drug Report has seen MPs call for a review of drug scheduling in...
A new study investigating a single dose of psilocybin for the treatment of major depressive disorder (MDD) has shown clinically significant levels of reduction in depressive...
